Adagene Inc (ADAG)

Currency in USD
4.470
-0.310(-6.49%)
Closed·
4.4700.000(0.00%)
·
ADAG is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
4.4084.780
52 wk Range
1.3004.850
Key Statistics
Prev. Close
4.78
Open
4.65
Day's Range
4.408-4.78
52 wk Range
1.3-4.85
Volume
81.65K
Average Volume (3m)
246.49K
1-Year Change
141.6216%
Book Value / Share
0.75
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
ADAG Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
9.400
Upside
+110.29%
Members' Sentiments
Bearish
Bullish
ProTips
Analysts anticipate sales growth in the current year

Adagene Inc News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Buy
Technical Indicators
Buy
Moving Averages
Buy

Analyst Ratings

5 Buy
1 Hold
0 Sell
Ratings:
6 analysts
Overall Consensus
Strong Buy

Analysts 12-Month Price Target:

Average 9.400
(+110.29% Upside)
Firm
ArticlePositionPrice TargetUpside / DownsideFrom Price TargetActionDate
H.C. Wainwright
Buy7.00+56.60%-MaintainApr 07, 2026
Guggenheim
Buy10.00+123.71%9.00MaintainApr 06, 2026
Leerink Partners
Buy8.00+78.97%7.00MaintainApr 02, 2026
Guggenheim
Buy9.00+101.34%-New CoverageNov 24, 2025
Lucid Capital Markets
Buy9.00+101.34%-New CoverageSep 18, 2025

Earnings

Latest Release
Jun 03, 2026
EPS / Forecast
-0.10 / -0.25
Revenue / Forecast
-- / --
EPS Revisions
Last 90 days

ADAG Income Statement

Compare ADAG to Peers and Sector

Metrics to compare
ADAG
Peers
Sector
Relationship
P/E Ratio
−16.8x−4.7x−0.4x
PEG Ratio
−0.34−0.120.00
Price/Book
8.4x2.6x2.6x
Price / LTM Sales
38.5x21.6x3.1x
Upside (Analyst Target)
79.0%122.2%48.8%
Fair Value Upside
Unlock8.4%6.3%Unlock

Adagene Inc., a clinical stage biotechnology company, engages in the research, development, and production of monoclonal antibody drugs for cancers in the People’s Republic of China. Its lead product candidate is the ADG126, a masked fully-human anti-CTLA-4 mAb which is in phase 1b/2 clinical development for the treatment of cancer. The company also develops ADG116, a fully human anti-CTLA-4 antibody generated using NEObody technology, which is in phase 1b/2 clinical trials to treat advanced/metastatic solid tumors; ADG206, which is in phase 1 clinical development to treat advanced metastatic solid tumors; ADG104, anti-PD-L1 monoclonal antibody which is in phase 2 clinical development; and ADG125, a novel anti-CSF-1R mAb which is in Phase 2 clinical development. In addition, it is developing ADG138, a HER2xCD3 POWERbody which is in pre clinical trial to treat low expressing tumors, as well as resistant/refractory tumors; ADG152, a CD20xCD3 POWERbody which is in preclincal trial to treat off-tumor toxicities; ADG153, a masked anti-CD47 IgG1 SAFEbody, wihx is in preclinical trial for the treatment of hematologic and solid tumor; and CD28 T-cell engagers, an anti-CD28 bispecific POWERbody TCEs to treat solid tumors. Adagene Inc. was incorporated in 2011 and is headquartered in Suzhou, China.

Ownership

Ownership Overview

Type
Common Stock Held% of Shares OutstandingMarket Value
Mutual Funds & ETFs
58.36K0.09%260.88K
Other Institutional Investors
49.51M74.94%221.33M
Public Companies & Retail Investors
16.50M24.97%73.75M
Total
66.07M100.00%295.34M

Top Holders

Holder
% of holding
Shares Held
Date Reported
Value (In 1,000s)
Han 2020 Irrevocable Trust11.37%7,512,35133,580
Janus Henderson Group plc10.09%6,666,66629,800

People Also Watch

300.71
SIMO
-5.13%
11.62
XNDU
-1.94%
41.66
VIAV
-11.49%
422.46
CIEN
-8.65%
190.89
AVAV
+10.70%

FAQ

What Is the Adagene (ADAG) Stock Price Today?

The Adagene stock price today is 4.470 USD.

What Stock Exchange Does Adagene Trade On?

Adagene is listed and trades on the Nasdaq Stock Exchange.

What Is the Stock Symbol for Adagene?

The stock symbol for Adagene is "ADAG."

What Is the Adagene Market Cap?

As of today, Adagene market cap is 295.340M USD.

What Is Adagene's Earnings Per Share (TTM)?

The Adagene EPS (TTM) is -0.375.

When Is the Next Adagene Earnings Date?

Adagene will release its next earnings report on Sep 02, 2026.

From a Technical Analysis Perspective, Is ADAG a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.

How Many Times Has Adagene Stock Split?

Adagene has split 0 times.

How Many Employees Does Adagene Have?

Adagene has 128 employees.

What is the current trading status of Adagene (ADAG)?

As of Jul 05, 2026, Adagene (ADAG) is trading at a price of 4.470 USD, with a previous close of 4.780 USD. The stock has fluctuated within a day range of 4.408 USD to 4.780 USD, while its 52-week range spans from 1.300 USD to 4.850 USD.

What Is Adagene (ADAG) Price Target According to Analysts?

The average 12-month price target for Adagene is 9.400 USD, with a high estimate of 14 USD and a low estimate of 7 USD. 5 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Strong Buy. The stock has an +110.29% Upside potential.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2026 - Fusion Media Limited. All Rights Reserved.